Biotech IV Monitor

CLDX — Celldex Therapeutics Inc.

$2.8B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for Celldex Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is June 2028.

Next readoutJune 2028in ~19 months
Upcoming readouts22 Phase 3
Market cap$2.8B
Cash & investments$650M~9 quarters at last loss rate
Recent 8-K filings1latest 2026-11-05

Upcoming readouts

Phase 3 Barzolvolimab
Chronic Inducible Urticaria; Cold Urticaria · NCT07266402
June 2028
Recruiting
Phase 3 barzolvolimab
Chronic Spontaneous Urticaria · NCT07256392
September 2028
Enrolling

Cash position

Celldex Therapeutics Inc. reported $650M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $76M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05

Discussion

No messages yet. If you follow CLDX, you can start the conversation.
Track CLDX in real time
See live implied volatility for CLDX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on CLDX
Contact — questions or corrections about CLDX: dukeupt@gmail.com